Bayer Animal Health announces the launch of Coraxis™ (moxidectin) Topical Solution for Dogs, a prescription-only, monthly transdermal product that prevents heartworm disease and treats and controls hookworms, roundworms, and whipworms in dogs. The product is expected to be available for sale in early February.
“Coraxis™ is a unique addition to the veterinarian’s anti-parasite toolbox,” said Robert Zolynas, DVM, MBA, Head of Research and Development North America for Bayer Animal Health. “Its transdermal formulation is rapidly absorbed, achieving and sustaining high plasma levels of moxidectin to continuously kill incoming heartworm larvae for thirty days. This important feature along with its broad-spectrum intestinal worm protection, make it a versatile and useful product.”
Administered monthly, Coraxis™ is a prescription drug that should be administered on the order of a veterinarian. It provides veterinarians more flexibility in creating parasite protection plans for dogs. Coraxis™ is available in five different sizes and is for use in dogs and puppies 7 weeks of age and older weighing between 3 to 110 pounds.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.us.
Bayer Animal Health